FDA moves to warn GLP-1 users about rare optic nerve injury linked to sudden vision loss
The US Food and Drug Administration has ordered makers of several widely used GLP-1 medicines to add warnings about nonarteritic anterior ischemic optic neuropathy, or NAION, a rare eye disorder that can cause sudden, painless blindness in one eye. The labels for Ozempic, Wegovy, Mounjaro and Zepbound must now alert prescribers and patients to the possibility of this event.
NAION occurs when blood vessels that supply the optic nerve become blocked, cutting off oxygen to tissue that depends on continuous perfusion. Once that optic nerve injury occurs, vision loss can be permanent. The condition is already the most common cause of acute optic nerve injury in people over 50, and there is no known treatment that reverses the damage after it develops.
A warning label does not settle the causality question. It does, however, change the conversation at the bedside, where patients using these drugs for diabetes, obesity or cardiovascular risk reduction need to know which symptoms require urgent evaluation.
A rare adverse event enters the label after FDA review
The FDA said it reviewed reports of NAION among people taking GLP-1 medicines along with additional studies before concluding that there is an increased risk of rare NAION events in users of these drugs. The agency did not identify a mechanism. It also recognized a major interpretive problem: people with obesity and type 2 diabetes often carry vascular risk factors that can independently raise the chance of NAION, making it difficult to disentangle drug effect from underlying disease burden.
That uncertainty is central to the current debate. GLP-1 drugs are prescribed to people who already live with hypertension, diabetes, dyslipidemia and sleep apnea far more often than the general population does, and each of those conditions can affect microvascular health. In that setting, an association with optic nerve ischemia can be real without being simple.
The American Academy of Ophthalmology said the added risk appears small and that a causal link has not been established. Its advice is direct: patients should not stop therapy without speaking to a clinician, but sudden painless vision loss in one eye warrants prompt ophthalmologic assessment.
One sentence matters more than the rest for patients: sudden, painless monocular vision loss is an emergency.
Why ophthalmologists are watching this signal closely
NAION is clinically frustrating because it often presents abruptly and without pain. Patients may wake up with blurred or dim vision in one eye, and by the time they seek help, the injury to the optic nerve may already be complete. The optic nerve is highly dependent on blood flow, so even a transient interruption can leave lasting damage.
For ophthalmologists, the label change is less about panic than pattern recognition. A rare event with catastrophic consequences deserves explicit warning when a medicine is used by millions of people. Even if the absolute risk remains low, the cost of missing the diagnosis is high: there is no proven way to restore sight after NAION.
Novo Nordisk, which manufactures Wegovy, said the available data do not establish a cause-and-effect relationship. The company also said it continues to monitor safety. That position reflects the limits of spontaneous reports and observational data, especially when baseline cardiovascular and metabolic disease can cloud the signal.
Earlier studies raised concern, but the evidence remains incomplete
The FDA’s action follows research that has kept the issue under scrutiny. A study published two years ago that analyzed 17,000 patients found that people taking semaglutide were four times more likely to be diagnosed with NAION than those not taking the drug. The finding attracted attention because semaglutide is a key ingredient in several GLP-1 medicines used for diabetes and weight loss.
Even so, one of the study’s authors, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, called the findings significant but tentative and said more research was needed in a more diverse population. That caution fits the design of the available evidence. Observational studies can identify a signal, but they cannot fully remove confounding by indication, disease severity, or differences in baseline vascular risk.
European regulators have also moved cautiously. Last year, a safety committee at the European Medicines Agency said up to 1 in 10,000 people taking semaglutide may be affected by NAION. That estimate frames the event as rare, yet serious enough to deserve a label warning.
What the warning means for patients already taking GLP-1 therapy
For patients, the practical message is not to abandon treatment. GLP-1 medicines offer important benefits for people with diabetes, obesity and heart disease, and abrupt discontinuation can undo glycemic and weight-related gains that matter for long-term health. The safer approach is to continue treatment unless a clinician advises otherwise, while staying alert to visual symptoms that demand immediate care.
For clinicians, the label adds one more item to a long list of adverse effects that already includes pancreatitis and gallbladder disease. It also sharpens the need for medication review in any patient who develops acute visual change. A sudden field defect or unilateral blur should not be assumed to be benign, and it should not be attributed automatically to refractive error, migraine or fatigue.
The question now is not whether GLP-1 therapy is broadly useful. It is. The question is how rare the optic nerve risk really is across different populations, which patients are most vulnerable, and whether certain vascular profiles, diabetic complications or concurrent medications increase susceptibility. Those answers will require better phenotyping and larger datasets than the current reports provide.
Until then, the label change functions as a clinical warning grounded in a plausible vascular mechanism and an unresolved epidemiologic signal. Patients on GLP-1 drugs who notice sudden painless vision loss need urgent ophthalmic evaluation, and prescribers should treat the symptom as a potential optic nerve emergency rather than a routine side effect.